Cancer Research
Newswire |
LONDON, September 24 /PRNewswire/ -- Clinicians and patient groups have welcomed today's announcement by the National Institute of Health and Clinical Excellence (NICE) recommending Pradaxa(R) (dabigatran etexilate) as an option for the primary prevention of venous thrombembolic events in adults who have undergone elective total hip or total knee replacement surgery.(1) This positive NICE appraisal coincides with the recent publication of a government venous thromboembolism (VTE) risk assessment tool recommended for all patients admitted to hospital in England by the Department of Health.(2…
Professor Ron Appel, speaking at the 10th anniversary conference of the Swiss Institute of Bioinformatics in Berne, Switzerland, says they have completed the annotation of human proteins.
Where the Human Genome Project produced a dictionary, this new work is more like an encyclopedia because it looks at life as it is really organized in our body at the molecular level, which will speed up scientific work that aims to improve our quality of life, like how we can combat genetic-based diseases.
Professor Amos Bairoch, head of the SIB's Swiss-Prot group said: "If human DNA is the script of life,…
Newswire |
BAGNOLS-SUR-CÈZE, France, September 23 /PRNewswire/ --
- Company's Expertise in Chromogranin A Tumor Detection Marker Technology Now Applied to Universal Technique
CISBIO Bioassays, a member of IBA group and a developer and marketer of diagnostic assays for the quantification of tumor markers, announced today the launch of its chromogranin A ELISA diagnostic tool, Chromoa. This ELISA kit complements CISBIO's existing chromogranin A RIACT kit and can be used by all laboratories for the detection and monitoring of neuroendocrine tumors.
Chromoa is a highly-sensitive, monoclonal antibody-based…
Newswire |
GENEVA, Switzerland, September 23 /PRNewswire/ --
- PREDICT Aims to Identify Potential Genetic Markers and Additional Serum Biomarkers That Could Play a Role in Predicting the Response to Growth Hormone Treatment in Children With Growth Hormone Deficiency or Turner Syndrome
- Results Will be Used in the Development of a Novel Pharmaco-Prediction Model to Optimize Growth Hormone Therapy
Merck Serono, a division of Merck KGaA, Darmstadt, Germany, today presented the results of the PREDICT study at the 47th Annual Meeting of the European Society for Paediatric Endocrinology (ESPE) in Istanbul,…
Newswire |
AURORA, Ontario, September 22 /PRNewswire/ --
Helix BioPharma announced today that it has received the necessary regulatory approvals to open clinical sites in Germany to expand upon its clinical trial with Topical Interferon Alpha-2b in patients with ano-genital warts, which is presently underway in Sweden.
"We are pleased to have received approval to open these additional clinical sites," said John Docherty, President of Helix BioPharma. "The opening of sites in Germany will grant us access to expanded clinical resources and a larger patient pool in order to enhance the recruitment rate of…
Newswire |
AMSTERDAM, September 22 /PRNewswire/ -- Kiadis Pharma announced today that its lead product ATIR(TM) has been granted orphan drug designation (ODD) by the European Medicines Agency (EMEA) for the prevention of acute Graft versus Host Disease (GvHD) following an allogeneic bone marrow transplantation.
"Following the orphan drug designation granted by the FDA for our lead product ATIR(TM), this is another important milestone in the development of ATIR(TM) as a novel approach which may enable a safe and potentially life-saving mismatched bone marrow transplantation as a treatment option for end…
Newswire |
GENEVA, Switzerland, September 22 /PRNewswire/ --
- Study Meets Primary Endpoint by Demonstrating Significant Effect of new Formulation of Rebif(R) on Disease Activity as Measured by MRI After 16 Weeks of Treatment
- Data Presented at Late-Breaking Session of the World Congress on Treatment and Research in Multiple Sclerosis in Montreal, Canada
Merck Serono, a division of Merck KGaA, Darmstadt, Germany, announced today that the ongoing IMPROVE (Investigating MRI Parameters with Rebif imprOVEd formulation) study met its primary endpoint. The primary objective of the study was to evaluate the…
Newswire |
WILMINGTON, Massachusetts, September 22 /PRNewswire/ --
Xenon Corp., a company internationally recognized as a leader and pioneer in the field of Pulsed Light systems, might have found the silver bullet that researchers have been seeking to increase vitamin D in their fight against disease.
It's called Pulsed light. It's brighter than the sun and in short pulses -- flashed on mushrooms -- increases the vitamin D content in mushrooms substantially.
Dole, the world's largest producer and marketer of fresh fruits and vegetables, has been treating Portobello and other mushroom varieties with…
There are more bacteria in our bodies than there ever have been people on the Earth. In fact, there are more bacteria in the colon than there are human cells in our bodies. Most of the bacteria in our guts are harmless and many are beneficial to our health. However, for several decades scientists have thought that some microbes living in the gut may play a role in the formation of sporadic colorectal cancer.
Research published in the October issue of the Journal of Medical Microbiology says they have discovered that a molecule produced by a common gut bacterium activates signalling pathways…
Newswire |
PARIS, September 18 /PRNewswire/ --
- Additional Analysis Shows HUMIRA Effectively Treats Adult Patients with Moderate to Severe Psoriasis Regardless of Age, Duration of Disease, Diagnosis of Psoriatic Arthritis or Recent Systemic Therapy
More psoriasis patients achieve efficacy when they receive continuous treatment with HUMIRA(R) (adalimumab) compared to patients who interrupt their therapy, according to data presented at the European Academy of Dermatology and Venereology (EADV) Congress in Paris. The findings were from a sub-analysis of Abbott's pivotal, 52-week study, REVEAL (The…